What You Should Know:

– Debiopharm, a leading independent biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a pioneer in AI-powered drug discovery, today announced a groundbreaking partnership to propel the development of a cutting-edge cancer drug.

– This strategic partnership combines Debiopharm’s deep pharmaceutical expertise with TNL’s revolutionary AI Digital Cells Lab platform, unlocking new frontiers in cancer treatment innovation.

Unlocking the Hidden Potential of a Promising Drug

The partnership focuses on unlocking the full potential of one of Debiopharm’s promising cancer drugs. By leveraging TNL’s AI-powered platform, the collaboration will explore:

• Expanding Indications: TNL’s platform will identify potential new applications for the drug, extending its reach and impact on cancer patients.
• Combination Therapy Optimization: Utilizing AI digital knockdowns, the team will identify synergistic combinations with other drugs in development, maximizing the therapeutic efficacy of Debiopharm’s cancer drug.
• Mechanism of Action Validation: TNL’s digital cell clones will provide a deeper understanding of the drug’s mechanism of action, ensuring targeted and effective treatment strategies.
• Comparative Analysis: Digital cell clones will enable side-by-side comparisons with existing cancer treatments, providing valuable insights for optimal drug selection and development.
• Biomarker Discovery: The partnership will focus on identifying predictive biomarkers that can guide patient selection and treatment personalization, ultimately improving patient outcomes.

“This partnership represents a significant leap forward in cancer drug development,” said Bertrand Ducrey, CEO of Debiopharm. “By combining our expertise with TNL’s innovative AI platform, we are confident in unlocking the full potential of this promising drug and bringing it to even more patients in need.”

What You Should Know:

• Vita Health, the first provider of clinically validated suicide prevention through innovative care management, announced today the close of a $22.5M Series A funding round.
• The funding will support the rapid expansion of life-saving services targeting youth and adults nationwide. The Vita behavioral health care pathways are based on the founding team’s successful clinical trials published in JAMA, The American Journal of Psychiatry and thousands of patient encounters demonstrating reductions in suicide attempts by more than 60% and deaths by up to 80%.

Diverse Consortium Backs Vita Health’s Specialized Telehealth Solutions for Mental Health Crisis

A diverse group of investors, including LFE Capital, Athyrium Capital Management, Flare Capital Partners, CVS Health Ventures, CU Healthcare Innovation Fund, Connecticut Innovations, and HopeLab, participated in the funding round for Vita Health. Vita Health initially aimed to tackle the rising suicide rates across all age groups but has expanded its mission to address the broader youth mental health crisis, covering conditions such as anxiety and depression.

 Suicide ranks as the second leading cause of death among teens and college students, and is a top-five killer for adults, according to the Center for Disease Control and Prevention. In 2021, there were over 1.7 million suicide attempts in the US. Vita Health stands out as the only telehealth provider specializing in suicide care, while also offering teletherapy and psychiatry services for various behavioral health conditions. Founded by a consortium of leading suicide risk experts and seasoned behavioral health innovators, Vita Health’s approach aims to address the root causes behind suicide.

“Our collective motivation was to shift a very deadly curve in our society that has far reaching and lasting implications for all involved,” says Vita Health co founder and chief executive officer, Lynn Hamilton. “We are humbled by the participation from a broad group of sophisticated, experienced, and strategic investors. With a growing roster of health plan partners, provider partners, employers, colleges and universities, we are expanding our reach to directly address the most challenging mental health problems in the U.S.”

What You Should Know:

• Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.
• Deepcell will incorporate NVIDIA AI into its single cell analysis technology, working collaboratively with NVIDIA to codevelop new uses for generative AI and multimodal applications in cell biology. The joint collaboration aims to advance understanding of cell morphology, and ultimately accelerate the use of AI-powered cellular analysis in cell biology and translational research across a broad swath of applications including cancer, stem cell, and cell therapy.

 Revolutionizing Life Sciences Through Cutting-Edge AI Collaboration

Deepcell, in partnership with NVIDIA, is poised to revolutionize life sciences by harnessing the power of multimodal generative AI. This collaboration aims to develop innovative algorithms, utilizing NVIDIA’s Clara suite and computing expertise, to enhance cell image analysis. Deepcell’s REM-I platform, set to be fully commercialized in 2024, integrates high-dimensional cell morphology analysis and sorting capabilities, enabling groundbreaking discoveries in cancer biology, developmental biology, stem cell biology, gene therapy, and more. The synergy between Deepcell’s technological strengths and NVIDIA’s resources promises to usher in a new era of insights and advancements in the field.

“Deepcell has catalyzed the field of morpholomics and showcased the benefits of a

revolutionary new method for single-cell analysis using brightfield cell imaging and artificial

intelligence,” said Mahyar Salek, Ph.D., Cofounder, President, and Chief Technology Officer at

Deepcell. “As we look to the future, we see many possibilities for incorporating multimodal and

generative AI into our platform, and leveraging our proprietary database of billions of cell

images to train additional AI models. Our relationship with NVIDIA will help us accelerate such

enhancements, and bring these advancements to our customers, enabling new discoveries at

unprecedented speed.”

What You Should Know:

– The year 2023 saw a stark shift in the digital health funding landscape, according to Rock Health’s annual year-end digital health funding report. Gone were the days of exuberant funding rounds and endless optimism.

– Instead, we witnessed a contraction, with venture capital drying up and startups scrambling to stay afloat. But amidst the turbulence, there were also signs of resilience, innovation, and a necessary course correction.

2023: A Year of Transition and Creative Measures

• Funding Plunges: Annual digital health venture funding reached a four-year low of $10.7B, with fewer deals and smaller amounts.
• M&A Activity Remains Muted: Despite expectations of a surge in acquisitions, the pace remained surprisingly slow.
• No Startup Apocalypse: While shutdowns were anticipated, most companies managed to weather the storm through creative financing tactics like extension rounds, unlabeled raises, and even “silent deals” with existing investors.
• IPO drought: No digital health companies went public in 2023, adding to the uncertainty.

2024: Facing Reality and Embracing Change

• Labeled Rounds Return, But with Adjustments: Startups that bought time in 2023 will need to raise again, likely at lower valuations and with a renewed focus on outcomes and commercial viability.
• M&A Takes Center Stage: Expect to see more mergers and acquisitions, as cash-strapped companies seek exits and larger players consolidate the market.
• Public Market Recalibration: Delistings are likely for struggling companies, while strong performers may finally aim for IPOs, leading to a more stable public health tech sector.
• Tough Choices and New Beginnings: Some startups will close their doors, but their talent and ideas will live on, potentially fueling new ventures or innovations within established companies.
• Emerging Segments Take Flight: Areas like digital obesity care and value-based care enablement, which saw early traction in 2023, could become the next big thing in 2024.

The Road Ahead: A More Efficient and Sustainable Ecosystem

The coming year will be a period of reckoning for the digital health industry. While some may see it as a harsh reality check, it’s also an opportunity for a much-needed reset. By weeding out weaker players and forcing innovation through resourcefulness, 2024 could pave the way for a more efficient, sustainable, and ultimately, more impactful digital health ecosystem.

Escalating competition for clinical trial sites, in tandem with other industry-wide challenges such as changing regulations; a lack of bandwidth and resources; identifying ideal sites and recruiting and retaining patients, are posing significant obstacles for sponsors and site teams within a global study portfolio, particularly in relation to clinical trial payments. Factors such as decentralized clinical trials, inflation and site attrition contribute to inconsistencies and financial confusion, especially with outdated payment solutions.

To address these persistent challenges, sponsors can leverage modern clinical trial payment solutions. The development of innovative approaches supports a comprehensive global strategy, the goal being to reduce the administrative burden associated with site payment processes. By adopting proven solutions, sponsors can be confident in ensuring timely and consistent payments for each trial, thereby minimizing queries and disputes from sites. 

This transformation is made possible through fully integrated systems that provide on-demand access to payment information, ultimately contributing to elevated levels of site satisfaction.

Navigating the Global Complexities and Dilemmas of Clinical Trial Payments

Clinical trial payment processes currently face several challenges that can adversely impact trial efficiency, precision and site satisfaction. Significant obstacles across their trial portfolios include:

• The Impact of Increased Competition and Geographic Diversity: Fierce competition for trial sites has created serious obstacles. According to research from Bain, 53% of the sites lack adequate bandwidth to actually run clinical trials. This is in stark contrast to just 14% before the Covid-19 pandemic and 47% at the pandemic’s peak. This heightened competition forces sites into difficult decisions, often leading to the rejection of trial opportunities. The complexity is further compounded by conducting trials across diverse geographic locations, evidenced by a 39% increase in the mean number of countries per Phase III clinical trial. Additionally, Phase II and Phase III trials see increases of 41% and 25%, respectively, in the number of investigative sites.

• The Current Clinical Trial Environment and its Influence on Payments: The influence of payment periods becomes evident with more than 80% of sites wanting a 30-day payment schedule. The reality is that evolving trial environments also introduce new intricacies to site payments, with factors such as decentralized clinical trial elements, high inflation rates and site attrition making trial protocols more complex. Splitting payments between sites and vendors can result in inaccuracies, hampering internal and site reporting capabilities. Further, legacy payment solutions prove inadequate, lacking the transparency and efficiency required to effectively address the diverse challenges associated with site payments.

• Dynamic Economic and Political Environments: Economic conditions prompt sites to request additional budget items, impacting payment schedules and cash flow for CROs and sponsors. Varying levels of economic development and legal systems lead to potential fraud and currency control complications as well. Changes in domestic affairs, including political and social unrest and governmental structural shifts, directly impact site relationships and payment capabilities, necessitating careful navigation to ensure seamless global payments.

Legacy payment solutions are starting to reach the end of their life cycle and, as they stand, are not equipped to address this extensive array of challenges. So, to handle payments across sites and clinical trials, sponsors must opt for strategic solutions to enhance the effectiveness of the full trial payment process.

A Contemporary Approach to Streamlining Clinical Trial Payments

Sponsors must embrace comprehensive solutions that simplify payment processes, enhance transparency and ensure precise and prompt compensation for clinical trial sites. 

Transitioning to advanced trial payment solutions enables sponsors to achieve:

• Enhanced Payment Efficiency: Modern clinical trial payment solutions significantly boost payment efficiency through diverse features and capabilities. Systematic alignment of protocol structures and triggers for payable visits ensures accurate and timely compensation. Features such as Electronic Data Capture (EDC) import, data reconciliation and automated payment calculation streamline processes. The Extract-Transform-Load (ETL) approach automates payments, providing sponsors with on-demand access to payment information and detailed reports by country, payee and currency, thereby enhancing transparency for strong financial management.

• Comprehensive Oversight: Modern clinical trial payment solutions ensure transparency and traceability at every stage of the clinical trial. User-friendly payment portals grant sites 24/7 access to complete payment information, fostering increased visibility and accountability. The integration of key clinical data from EDC systems, study budgets, agreements and schedules of events enables automated invoicing for streamlined efficiency and prevent payment errors. Systematic alignment of protocol structures and payable visit triggers, along with EDC import, data reconciliation and payment calculation, ensures smooth operations.

• Consistency across the payments’ lifecycles to increase total ROI: Through the new approach sponsors can help improve tax planning and management as well as cash flow. They can reduce the burden on clinical and financial staff for payments, disputes, reporting and reconciliations, all while minimizing site and study overall costs and overpayments. 

By adopting a modern approach and leveraging advanced trial payment solutions, sponsors benefit from a combination of expertise and cutting-edge technologies that drive cost and performance efficiencies. This shift also contributes to higher rates of site satisfaction, alleviating the burden on clinical operations and allowing personnel to concentrate entirely on clinical trial management.

Optimizing the Path Forward for Site Payments

The growing intricacy of clinical trials, heightened competition for sites and geographical diversity have rendered conventional payment methods unwieldy and ineffective. Through consolidation, the streamlining of payment processes becomes possible, guaranteeing investigators receive precise and timely compensation. This, in turn, fosters improved trial conduct and overall success.

About Jim DiCesare

Jim DiCesare is passionate about delivering innovative site activation and site payment services to clinical trials. With over 25 years of industry experience leading clinical operations teams at Merck, DrugDev, and now IQVIA Technologies, Jim has expertise across the contracting, budgeting, and investigator grant payment management continuum. He is a frequent speaker at industry conferences and has written for a variety of publications. Jim earned a B.S. in Accounting from Kutztown University.

What You Should Know:

– Arineta Cardio Imaging, a pioneer in cutting-edge cardiovascular imaging solutions, has appointed seasoned medical device leader Doug Ryan as its new CEO.

– Ryan brings 30 years of expertise in building business infrastructure and crafting market strategies for global healthcare giants, poised to propel Arineta to new heights in the fight against cardiovascular disease.

Proven Track Record of Success

Prior to joining Arineta, Ryan held pivotal leadership positions at industry giants like Siemens Healthineers and Samsung Electronics. At Siemens, he spearheaded the expansion of their Computed Tomography business, while at Samsung, he led the Health and Medical Equipment group. His earlier success in launching multi-slice CT in the U.S. for Toshiba American Medical Systems demonstrates his proven ability to translate innovative technology into tangible market impact.

Driving Innovation for Life-Saving Technology

Ryan’s passion for Arineta stems from its dedication to providing the highest quality cardiac and thoracic CT imaging. The company’s flagship SpotLight and SpotLight™ Duo scanners, the world’s only dedicated cardiovascular CT systems, offer unmatched benefits. Their unique combination of temporal resolution, coverage, and cost-effectiveness positions them as groundbreaking solutions in the field.

“Arineta’s vision deeply resonates with me,” says Ryan. “There are still thousands of patients worldwide who lack access to life-saving technology like the SpotLight Cardiac CT. With its speed, quality, and accuracy, Arineta’s solutions have the potential to save lives, and it’s our mission to make them globally accessible.”

What You Should Know:

– Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company acquires C2i Genomics, Inc., a pioneer in minimal residual disease (MRD) detection.

– Under the terms of the agreement, Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones over the next two years, payable in Veracyte shares or cash at Veracyte’s election.

– This strategic move positions Veracyte to significantly expand its offerings across the cancer care continuum, offering a more comprehensive and personalized approach to cancer management.

Taking MRD Detection to the Next Level

Early detection of MRD recurrence can lead to early intervention and improved survival rates for patients. C2i’s technology analyzes entire genomes, generating broader and more accurate MRD signatures compared to traditional methods. This allows for earlier detection of tumor recurrence, leading to potentially better patient outcomes. C2i’s tests require only a small blood sample and deliver results in as little as two weeks, significantly faster than many existing methods. This translates to quicker treatment adjustments and improved patient anxiety management.

Unlocking the Potential of Early Detection

Veracyte plans to leverage C2i’s technology to develop MRD tests for other high-impact cancer indications, further solidifying its position as a leader in precision oncology. This acquisition builds on Veracyte’s existing portfolio of diagnostic and prognostic tests, allowing it to offer a more comprehensive suite of tools for managing cancer throughout the patient journey. By providing accurate and timely information about MRD status, Veracyte empowers clinicians to tailor treatment plans, optimize patient outcomes, and minimize unnecessary interventions. Further integration of C2i Genomics’ technology is planned across multiple cancer indications, paving the way for a future where personalized cancer care becomes the standard, not the exception.

“MRD detection is a critical piece of the puzzle for monitoring treatment success and guiding future decisions,” says Marc Stapley, Veracyte CEO. “C2i Genomics’ technology holds immense potential to revolutionize patient care by enabling earlier detection of recurrence than ever before.”

What You Should Know:

– XRHealth, the leading healthcare platform in Spatial Computing, announced today a $6M funding round led by Asabys Partners, with participation from NOVA Prime Fund and XRHealth’s existing investors.

– This milestone follows the successful merger with Amelia Virtual Care, solidifying XRHealth’s position as the largest extended reality (XR) platform encompassing mental, physical, and occupational health.

VR/AR Meets Patient Needs

XRHealth’s platform leverages virtual clinics, immersive VR/AR experiences, and advanced data analytics to empower healthcare providers. Patients receive treatment from the comfort of their homes for a wide range of conditions, including acute and chronic pain, post-stroke rehabilitation, fibromyalgia, anxiety, stress, dementia, and more.

Growth Plans

The funding will support the integration of XRHealth and Amelia Virtual Care, creating a powerhouse platform for immersive healthcare experiences. In addition, the funding will fuel the development of an AI-powered clinician, alleviating the burden on human healthcare professionals and expanding access to care for millions globally.

“This funding empowers us to accelerate the growth of our platform, democratizing healthcare through immersive VR/AR technology and AI. We’re excited to pioneer an AI clinician in Spatial Computing, opening doors to a future where everyone receives quality care, regardless of location,” said Eran Orr, CEO of XRHealth.

What You Should Know:

• Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics, the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas. 

Expanding Horizons in Cost-Effective Whole Genome Sequencing

The collaboration aims to enhance patient access, affordability, and outcomes by expanding the use of cost-efficient whole genome sequencing, particularly in areas like solid-tumor minimal residual disease (MRD) testing. Quest plans to utilize Ultima’s technology, such as the UG 100™ System, to develop lab-developed tests, including its Haystack solid-tumor MRD™ technology.

 Ultima’s platform offers the capability to sequence an entire genome for $100 and stands out for its sensitivity in detecting rare cancer-related gene variants, particularly single nucleotide variants (SNVs). Quest, with its expertise in oncology, genomics, and pathology, along with a national scale in tumor biopsy and blood specimen collection, will contribute to the collaboration. The company, known for its comprehensive oncology services, aims to improve diagnostics and treatment monitoring for various health systems and providers in the United States.

“We are delighted to collaborate with the world’s leading diagnostics information services provider to deploy our technology toward lab-developed tests for applications benefiting from insights from whole genome sequencing,” said CEO Gilad Almogy. “Ultima’s technology was designed for applications requiring greater sequencing depth, breadth, or frequency and both MRD testing and whole genome sequencing are premier examples of these. Our unique advantages in SNV detection, combined with greater sequencing depth at lower cost can be transformational for oncology applications and MRD, as well as for cell-free DNA applications and applications with challenging samples. The collaboration with Quest emphasizes our focus on enabling the leading organizations that will help us scale our technology and, most importantly, benefit patients and providers.”

What You Should Know:

• Medtronic, a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system.
• The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology, and SenSight™ directional leads. The Percept™ family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinson’s disease, essential tremor, and dystonia as well as epilepsy. 

Medtronic’s Perception RC with BrainSense Spearheads Cutting-Edge Management for Pathological Tremor

DBS utilizes a surgically implanted medical device, resembling a cardiac pacemaker. Medtronic’s Percept™ neurostimulators employ slender wires to transmit electrical signals to specific brain targets affected by neurological disorders such as Parkinson’s disease. The Percept™ RC, the smallest and thinnest dual-channel neurostimulator for DBS, incorporates BrainSense™ technology to capture and record brain signals. 

This allows healthcare providers to tailor and personalize therapy based on evolving patient needs. The Percept™ RC battery, featuring Medtronic’s patented technology, offers a service life of at least 15 years with consistent and fast recharge performance, exhibiting less battery fade than other rechargeable devices. Patients can achieve rapid recharging from 10% to 90% full charge in less than an hour. Notably, Medtronic was the first in the U.S. to provide full-body MR Conditional DBS systems, enabling patients to undergo safe scans anywhere on the body under specific conditions. This is crucial as nearly 70 percent of all DBS-eligible patients may require an MRI as part of their essential care.

“Our DBS therapy with exclusive BrainSense™ technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments – something many of us unintentionally take for granted,” said Amaza Reitmeier, vice president and general manager, Brain Modulation within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “We are transforming brain modulation through sensing-enabled DBS and will continue to drive therapy innovation with the goal of many more peoples’ lives improved with Medtronic DBS therapy.”

What You Should Know:

• Butterfly Network, Inc. (“Butterfly”), a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced the FDA clearance of its next-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3.
• The new device is the company’s third iteration of the world’s first semiconductor-based single-probe, whole-body ultrasound system. Butterfly iQ3 features a brand-new ergonomic design and will deliver double the data processing speed for optimized image resolution, sensitivity and penetration, as well as faster 3D capabilities to power novel, automated image capture modes: iQ Slice and iQ Fan.

What You Should Know:

• Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionise healthcare and improve the human condition using molecular science and AI, and Flatiron Health, a leading health-tech company transforming evidence generation through an engaged care network, oncology-specific expertise, and fit-for-purpose scientific methods and tools, today announced a partnership to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care.
• As the pioneer in precision medicine and molecular profiling, Caris has created a molecular-rich, real-world database that contains more than 50 petabytes of oncology-specific genomic, transcriptomic, proteomic and imaging data. Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient tested. 

Accelerating Advancements for Cancer Drug Discovery

Combining the breadth and depth of Caris’ genomic, transcriptomic and imaging database with Flatiron’s industry-leading longitudinal patient data and high-quality clinical outcomes, backed by deep scientific expertise, equips cancer researchers with robust comprehensive real-world data (RWD) offering at scale to power the next wave of cancer therapeutics.

“We are excited to collaborate with Flatiron Health to create a multimodal data offering in support of biopharma’s efforts to bring novel personalized therapeutic interventions to market to ultimately improve the lives of cancer patients,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “In forming this data union, we are able to maximize biological and clinical context to better understand each patient journey.” 

What You Should Know:

• Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence and insights, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can so that patients don’t suffer while cures hide on the pharmacy shelf.
• The collaboration allows Every Cure to leverage GENEVA OS™ and data from the Atropos Evidence™ Network to confirm and enhance findings from their AI driven data platform in the real world. By doing this, it offers key real world signals and generation of AI model features to emulate the effect of therapies in real world populations. This rapid, high quality evidence generation dramatically accelerates the potential of yielding new uses for existing drugs and can accelerate clinical development by providing a real-world signal of patient response. 

Unlocking the Full Potential of Modern Medicine

Since its inception in 2023, the collaboration has pioneered a Real-World Data-driven approach named “Biology-in-Data Out” and “Data-in-Biology Out.” This method, employed by Every Cure, involves utilizing their AI platform to identify potential drug repurposing signals, which are then validated in real-world patients through the GENEVA OS and the Atropos Evidence Network. Recently featured in a Cell Publication by Dr. Dylan Dodd at Stanford University, this approach utilizes Atropos Health to confirm the impact of the antibiotic Bactrim on gout symptoms by analyzing shifts in gut bacteria populations.

Coinciding with the launch of Geneva OS™ and ChatRWD™, Atropos Health, a leader in life sciences, has also formed a Life Sciences Advisory Board featuring executives from prominent pharmaceutical companies such as Moderna and Novartis. Every Cure and other partners gain access to Atropos’ evidence generation tools through a federated installation of Geneva OS in their internal cloud data environment. This includes the Green Button Informatics Consult and access to Alexandria™, housing thousands of existing studies for rerunning on local data. Furthermore, Geneva OS incorporates the CRAFT Emulation Toolkit™, allowing users to enhance trial recruitment and analyze trial designs in real-world data, facilitating diverse subgroup analysis for optimizing study designs. CRAFT Emulation Toolkit accelerates evidence generation, maintaining Atropos Health’s commitment to swift insights.

What You Should Know:

– Amazon launches its new Health Condition Programs to simplify access to digital health benefits offered by insurance plans and employers.

– By partnering with companies like Omada Health, Amazon brings awareness and enrollment options directly to patients where they’re already looking for health information. This collaboration targets conditions like diabetes prevention, diabetes management, and hypertension, impacting millions of Americans.

How Amazon’s Health Condition Programs Work

– Effortless Discovery: Visit the Amazon Health webpage for a quick coverage check. If eligible, you’ll be guided toward relevant programs like Omada’s offerings for diabetes prevention, management, and hypertension control.

– Seamless Enrollment: No more navigating complex websites or phone calls. Amazon streamlines the enrollment process, making it easier to join Omada’s programs and unlock the potential for improved health outcomes.

– Personalized Support: Omada’s programs provide comprehensive support, including connected devices, health coaching, nutrition planning, and more. This holistic approach empowers individuals to manage their chronic conditions effectively.

More Than Just a Program

Amazon’s initiative tackles the crucial issue of low awareness surrounding digital health benefits, empowering individuals to take charge of their health. This innovative approach paves the way for a future where technology empowers patients, connecting them with the resources they need to manage chronic conditions effectively.

“Amazon wants to make it easier for people to get and stay healthy, and part of that is making it easier to discover the products, services, and professionals that can help them do that. Many people aren’t aware of the health care benefits they’re eligible for, that are typically no cost or subsidized by their employer or insurance plan,” said Aaron Martin, vice president of healthcare at Amazon. “When customers are shopping for health-related products on Amazon, we can surface these additional health care benefits to them to provide even more support in improving their health, at no additional cost.”

What You Should Know:

– Tandem Diabetes Care and Abbott have joined forces to bring the first automated insulin delivery (AID) system in the US compatible with Abbott’s latest FreeStyle Libre 2 Plus sensor.

– The integration brings the benefits of advanced closed-loop technology to millions of Americans living with diabetes, helping them achieve better blood sugar control and manage their condition with greater ease.

Seamless Integration for Precise Control:

The t:slim X2 insulin pump, equipped with Control-IQ technology, now wirelessly connects with the FreeStyle Libre 2 Plus sensor. This continuous glucose monitoring (CGM) system delivers minute-by-minute glucose data directly to the pump and its accompanying app. Control-IQ then utilizes this real-time information to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every five minutes, preventing both hyperglycemia and hypoglycemia.

Key benefits for users

– Reduced burden: The integration simplifies diabetes management by eliminating finger pricks and the need for separate CGM devices.

– Improved blood sugar control: Control-IQ’s proactive insulin adjustments help prevent high and low blood sugar levels, leading to better overall glucose management.

– Personalized experience: The system is highly customizable, allowing users to adjust settings to suit their individual needs and preferences.

Abbott’s Innovation

The FreeStyle Libre 2 Plus sensor boasts several features that make it ideal for AID compatibility:

– 15-day wear time: This extended wear period reduces the need for frequent sensor changes, offering convenience and cost savings.

– Proven accuracy: The sensor delivers highly accurate glucose readings, ensuring reliable data for Control-IQ’s algorithms.

– Discreet and comfortable: The sensor is small and lightweight, making it comfortable to wear for extended periods.

“Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the U.S.,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.”